| Literature DB >> 34065613 |
Sammar Alsaedi1, Bandar A Babgi1, Magda H Abdellattif2, Muhammad N Arshad3, Abdul-Hamid M Emwas4, Mariusz Jaremko5, Mark G Humphrey6, Abdullah M Asiri1,3, Mostafa A Hussien1,7.
Abstract
A set of copper(I) coordination compounds with general formula [Entities:
Keywords: Copper(I); DNA-binding; anticancer properties; dipyridophenazine; molecular docking
Year: 2021 PMID: 34065613 PMCID: PMC8161420 DOI: 10.3390/pharmaceutics13050764
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1General structures of copper(I) complexes employed in chemotherapy.
Figure 2Copper(I) complexes studied in this work.
Scheme 1Synthetic route to the copper(I) complexes.
Figure 3ORTEP diagram of Cu-1 with thermal ellipsoids drawn at the 50% probability level.
Figure 4Unit cell packing diagram for Cu-1.
Figure 5Overlaid absorption (left) and emission (right) spectra of complexes Cu-1–Cu-5.
Spectroscopic Data of Complexes Cu-1–Cu-5.
| Complex | Absorbance | Emission | ||
|---|---|---|---|---|
| λmax | ϵ | λem, | Relative Intensity | |
|
| 273 | 47.69 | 416 | 0.38 |
|
| 289 | 52.67 | 436 | 0.66 |
|
| 277 | 65.36 | 437 | 0.50 |
|
| 283 | 64.98 | 437 | 0.64 |
|
| 281 | 35.82 | 418 | 1.00 |
Intrinsic-Binding Constants and Competitive Quenching Constants for Cu-1–Cu-5.
| Complex | Substituent | UV-vis Spectroscopic Titration | Fluorescence Quenching Assay | ||
|---|---|---|---|---|---|
| Kb | Scaled Kb | Ksv | Scaled Ksv | ||
|
| H | 4.00 × 106 | 20 | 7.73 × 103 | 1.00 |
|
| NO2 | 4.44 × 106 | 22 | 8.93 × 103 | 1.16 |
|
| CN | 8.00 × 105 | 4 | 1.00 × 104 | 1.29 |
|
| Benzoyl | 8.00 × 105 | 4 | 5.53 × 103 | 0.72 |
|
| Dimethyl | 2.00 × 105 | 1 | 6.36 × 103 | 0.82 |
Ksv = quenching constant, Kb = intrinsic-binding constant.
Figure 6Quenching of EtBr-DNA adduct by Cu-1 (A), Cu-2 (B), and Cu-3 (C) (red solid lines are emission spectra of the EtBr-DNA adduct, while the blue lines are the emission spectra with increasing concentrations of the complexes. (a,b,c) Stern-Volmer plots of the quenching process of EtBr-DNA by Cu-1, Cu-2, and Cu-3.
Figure 7Determination of the binding modes of the compounds to DNA by viscosity assay.
Figure 8Cartoon illustration of the possible binding sites of the Cu-compounds as estimated by molecular docking modeling.
Figure 9Illustration of the non-covalent interactions (2D and 3D) of Cu-compounds with B-DNA as estimated by MOE.
Anticancer Activities of the Copper Complexes and Cisplatin Against M-14 and MCF-7 Cell Lines.
| Compounds | IC50 (µM) | |
|---|---|---|
| M-14 | MCF-7 | |
|
| 6.29 ± 0.05 | 8.69 ± 0.43 |
|
| 57.64 ± 0.05 | - |
|
| 45.20 ± 0.05 | - |
|
| 22.82 ± 1.04 | 11.93 ± 0.54 |
|
| 13.83 ± 0.46 | 9.85 ± 0.10 |
|
| 9.14 ± 0.05 | 7.33 ± 0.38 |
|
| 12.88 ± 0.09 | 8.43 ± 0.62 |
|
| 14.76 ± 0.31 | 11.52 ± 0.52 |